XML 41 R25.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Supplementary Quarterly Financial Data (Unaudited) | 12 Months Ended
--- | ---
Jun. 30, 2018
Quarterly Financial Data [Abstract] |
Supplementary Quarterly Financial Data (Unaudited) | 18. SUPPLEMENTARY QUARTERLY FINANCIAL DATA (UNAUDITED)
| As described in Note 2, "Revisions of Previously-Issued Financial Statements", amounts presented below reflect revisions to correct certain immaterial errors related to sales allowance.
In millions, except per share amounts |  | Quarters Ended |
|  | Jun 30, |  |  | Mar 31, |  |  | Dec 31, |  |  | Sep 30, |
Consolidated Statement of Operations Data: |  | 2018 |  |  | 2018 |  |  | 2017 |  |  | 2017 |
Molecular diagnostic testing |  | $ | 187.6 |  |  | $ | 177.3 |  |  | $ | 177.9 |  |  | $ | 176.5 |
Pharmaceutical and clinical services |  |  | 13.3 |  |  |  | 13.8 |  |  |  | 14.8 |  |  |  | 11.4 |
Total Revenue |  |  | 200.9 |  |  |  | 191.1 |  |  |  | 192.7 |  |  |  | 187.9 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 38.0 |  |  |  | 36.8 |  |  |  | 37.7 |  |  |  | 36.2 |
Cost of pharmaceutical and clinical services |  |  | 7.7 |  |  |  | 7.3 |  |  |  | 6.7 |  |  |  | 6.8 |
Research and development expense |  |  | 17.7 |  |  |  | 18.5 |  |  |  | 16.8 |  |  |  | 17.8 |
Change in the fair value of contingent consideration |  |  | 0.2 |  |  |  | (1.2 | ) |  |  | 13.0 |  |  |  | (73.2 | )
Selling, general and administrative expense |  |  | 121.4 |  |  |  | 115.1 |  |  |  | 115.4 |  |  |  | 115.2 |
Total costs and expenses |  |  | 185.0 |  |  |  | 176.5 |  |  |  | 189.6 |  |  |  | 102.8 |
Operating income |  |  | 15.9 |  |  |  | 14.6 |  |  |  | 3.1 |  |  |  | 85.1 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 0.5 |  |  |  | 0.5 |  |  |  | 0.4 |  |  |  | 0.4 |
Interest expense |  |  | (1.1 | ) |  |  | (0.5 | ) |  |  | (0.7 | ) |  |  | (0.9 | )
Other |  |  | 0.8 |  |  |  | (0.5 | ) |  |  | (0.4 | ) |  |  | (0.3 | )
Total other income (expense) |  |  | 0.2 |  |  |  | (0.5 | ) |  |  | (0.7 | ) |  |  | (0.8 | )
Income before income taxes |  |  | 16.1 |  |  |  | 14.1 |  |  |  | 2.4 |  |  |  | 84.3 |
Income tax provision |  |  | 3.0 |  |  |  | 4.5 |  |  |  | (26.3 | ) |  |  | 4.8 |
Net income |  |  | 13.1 |  |  |  | 9.6 |  |  |  | 28.7 |  |  |  | 79.5 |
Net loss attributable to non-controlling interest |  |  | - |  |  |  | (0.1 | ) |  |  | - |  |  |  | (0.1 | )
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | 13.1 |  |  | $ | 9.7 |  |  | $ | 28.7 |  |  | $ | 79.6 |
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.19 |  |  | $ | 0.14 |  |  | $ | 0.41 |  |  | $ | 1.16 |
Diluted |  | $ | 0.18 |  |  | $ | 0.13 |  |  | $ | 0.40 |  |  | $ | 1.13 |
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 70.1 |  |  |  | 69.8 |  |  |  | 69.3 |  |  |  | 68.6 |
Diluted |  |  | 72.9 |  |  |  | 72.4 |  |  |  | 71.9 |  |  |  | 70.4 |
In millions, except per share amounts |  | Quarters Ended |
|  | Jun 30, |  |  | Mar 31, |  |  | Dec 31, |  |  | Sep 30, |
Consolidated Statement of Operations Data: |  | 2017 |  |  | 2017 |  |  | 2016 |  |  | 2016 |
Molecular diagnostic testing |  | $ | 187.0 |  |  | $ | 183.0 |  |  | $ | 184.1 |  |  | $ | 166.5 |
Pharmaceutical and clinical services |  |  | 12.6 |  |  |  | 11.7 |  |  |  | 12.6 |  |  |  | 12.4 |
Total Revenue |  |  | 199.6 |  |  |  | 194.7 |  |  |  | 196.7 |  |  |  | 178.9 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 35.6 |  |  |  | 37.9 |  |  |  | 37.4 |  |  |  | 34.3 |
Cost of pharmaceutical and clinical services |  |  | 6.9 |  |  |  | 6.4 |  |  |  | 7.0 |  |  |  | 5.7 |
Research and development expense |  |  | 18.8 |  |  |  | 17.6 |  |  |  | 18.6 |  |  |  | 19.4 |
Change in contingent consideration |  |  | (2.7 | ) |  |  | 5.2 |  |  |  | (3.8 | ) |  |  | 0.5 |
Selling, general and administrative expense |  |  | 122.1 |  |  |  | 122.1 |  |  |  | 120.3 |  |  |  | 111.9 |
Total costs and expenses |  |  | 180.7 |  |  |  | 189.2 |  |  |  | 179.5 |  |  |  | 171.8 |
Operating income |  |  | 18.9 |  |  |  | 5.5 |  |  |  | 17.2 |  |  |  | 7.1 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 0.3 |  |  |  | 0.3 |  |  |  | 0.3 |  |  |  | 0.3 |
Interest Expense |  |  | (1.2 | ) |  |  | (1.5 | ) |  |  | (2.6 | ) |  |  | (0.7 | )
Other |  |  | (0.1 | ) |  |  | 1.5 |  |  |  | (2.6 | ) |  |  | (1.8 | )
Total other income (expense) |  |  | (1.0 | ) |  |  | 0.3 |  |  |  | (4.9 | ) |  |  | (2.2 | )
Income before income taxes |  |  | 17.9 |  |  |  | 5.8 |  |  |  | 12.3 |  |  |  | 4.9 |
Income tax provision |  |  | 5.8 |  |  |  | 3.0 |  |  |  | 6.2 |  |  |  | 5.6 |
Net income |  | $ | 12.1 |  |  | $ | 2.8 |  |  | $ | 6.1 |  |  | $ | (0.7 | )
Net loss attributable to non-controlling interest |  |  | (0.2 | ) |  |  | - |  |  |  | - |  |  |  | - |
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | 12.3 |  |  | $ | 2.8 |  |  | $ | 6.1 |  |  | $ | (0.7 | )
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.18 |  |  | $ | 0.04 |  |  | $ | 0.09 |  |  | $ | (0.01 | )
Diluted |  | $ | 0.18 |  |  | $ | 0.04 |  |  | $ | 0.09 |  |  | $ | (0.01 | )
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 68.2 |  |  |  | 68.1 |  |  |  | 68.2 |  |  |  | 68.8 |
Diluted |  |  | 68.9 |  |  |  | 68.3 |  |  |  | 68.3 |  |  |  | 68.8 |

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialDataAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration